Eteplirsen Approval Reflected FDA's Conflict On Accelerated Approval – Former Sarepta CEO

There is anxiety within the US agency over use of the pathway amid the prospect for confirmatory trials to fail, former CEO Garabedian says at FDA/CMS Summit.